Product Overview

Glimith MP 2 is a triple-combination oral antidiabetic formulation containing Glimepiride IP 2 mg, Metformin Hydrochloride IP 500 mg, and Pioglitazone Hydrochloride IP 15 mg. It is specifically formulated for the effective management of Type 2 Diabetes Mellitus in patients who require comprehensive glycemic control beyond monotherapy or dual-drug therapy. By combining three complementary mechanisms of action, the formulation helps regulate blood glucose levels while improving insulin function and overall metabolic control.

Glimepiride stimulates the pancreatic beta cells to release insulin, Metformin decreases hepatic glucose production and improves insulin sensitivity, while Pioglitazone enhances peripheral insulin sensitivity by increasing glucose utilization in muscle and adipose tissues. Together, these mechanisms provide effective control of fasting and postprandial blood glucose levels, helping reduce the risk of long-term diabetes-related complications.

Glimith MP 2 is commonly prescribed along with a balanced diet, regular exercise, and lifestyle modifications. The combination therapy simplifies treatment by reducing pill burden while improving treatment adherence, making it a valuable option for long-term diabetes management.

Manufactured under stringent pharmaceutical quality standards, Glimith MP 2 delivers consistent efficacy, safety, and reliability, supporting healthcare professionals in providing comprehensive diabetes care.

How It Works

Glimepiride stimulates insulin secretion from the pancreatic beta cells, helping lower blood glucose levels. Metformin Hydrochloride reduces glucose production by the liver, decreases intestinal glucose absorption, and improves insulin sensitivity. Pioglitazone Hydrochloride enhances the body’s response to insulin by increasing glucose uptake in peripheral tissues and reducing insulin resistance. Together, these complementary mechanisms provide comprehensive blood glucose control and support improved metabolic function.

Therapeutic Applications

Glimith MP 2 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Inadequately Controlled Blood Glucose Levels
• Long-Term Glycemic Management
• Combination Antidiabetic Therapy
• Insulin Resistance
• Patients requiring triple-mechanism glucose control

Key Benefits

• Triple-action therapy for comprehensive blood glucose management.
• Combines Glimepiride, Metformin, and Pioglitazone in a single tablet.
• Helps improve insulin secretion and insulin sensitivity.
• Supports effective control of fasting and postprandial blood glucose levels.
• Reduces pill burden and improves treatment adherence.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Glimith MP 2 undergoes comprehensive quality assurance and rigorous quality testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Glimith MP 2 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.